
Join to View Full Profile
325 Santa Ana AveSan Francisco, CA 94127
Phone+1 415-334-1427
Are you Dr. Stempien?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Mary Jean Stempien, MD is an internist in San Francisco, California. She is currently licensed to practice medicine in California, Connecticut, and Massachusetts.
Education & Training
- Sutter Health/California Pacific Medical CenterResidency, Internal Medicine, 1988 - 1991
- University of Massachusetts Medical SchoolClass of 1988
Certifications & Licensure
- CA State Medical License 1990 - 2025
- CT State Medical License 2018 - 2020
- MA State Medical License 1982 - 1990
Publications & Presentations
PubMed
- 107 citationsRandomized, placebo-controlled trial of ADS-5102 (amantadine) extended-release capsules for levodopa-induced dyskinesia in Parkinson's disease (EASE LID 3).Wolfgang H. Oertel, Karla Eggert, Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser
Movement Disorders. 2017-08-21 - 117 citationsADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson Disease (EASE LID Study): A Randomized Clinical Trial.Rajesh Pahwa, Caroline M. Tanner, Robert A. Hauser, Stuart Isaacson, Paul A. Nausieda
JAMA Neurology. 2017-08-01 - 40 citationsADS-5102 (Amantadine) Extended-Release Capsules for Levodopa-Induced Dyskinesia in Parkinson's Disease (EASE LID 2 Study): Interim Results of an Open-Label Safety Study.Robert A. Hauser, Rajesh Pahwa, Caroline M. Tanner, Wolfgang H. Oertel, Stuart Isaacson
Journal of Parkinson's Disease. 2017-01-01